A majority of primary myeloma patient samples and cell lines display an elevated expression of NF-κB target genes, including TRAF3, CYLD, BIRC2/BIRC3, CD40, NFKB1, or NFKB2, suggesting that addiction to NF-κB signaling is frequent in myeloma (Vrábel et al., 2019). Here, BIRC2 is linked to plasma cell myeloma.